Predictive and Prognostic Implications of Circulating CX3CR1⁺ CD8⁺ T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy.

ABSTRACT: Lack of reliable predictive biomarkers is a major limitation of combination therapy with chemotherapy and anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-1/PD-L1) therapy (chemo-immunotherapy). We previously observed that the increase of peripheral blood CD8⁺ T cells expressing CX3CR1, a marker of differentiation, correlates with response to anti-PD-1 therapy; however, the predictive and prognostic value of T-cell CX3CR1 expression during chemo-immunotherapy is unknown. Here, we evaluated the utility of circulating CX3CR1⁺CD8⁺ T cells as a predictive correlate of response to chemo-immunotherapy in patients with non-small cell lung cancer (NSCLC). At least 10% increase of the CX3CR1⁺ subset in circulating CD8⁺ T

SUBMITTER: Abdelfatah E 

PROVIDER: S-EPMC10060186 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature